High cholesterol medication
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
High Cholesterol Medication: Efficacy, Safety, and Trends
Statins: The Cornerstone of Cholesterol-Lowering Therapy
Prevalence and Usage Trends
Statins are the most commonly prescribed medications for lowering cholesterol. Between 2003 and 2012, the use of prescription cholesterol-lowering medications among adults aged 40 and over increased significantly, with statins being the predominant choice. By 2011-2012, 83% of adults using cholesterol-lowering medications were on statins alone, with simvastatin and atorvastatin being the most frequently used.
Efficacy and Safety
Statins are highly effective in reducing low-density lipoprotein cholesterol (LDL-C) and have been shown to significantly reduce the risk of cardiovascular events. The 2013 cholesterol treatment guidelines emphasize the use of statins based on LDL-C levels and cardiovascular risk factors. Despite their widespread use, statins are underutilized due to factors such as lack of awareness, fear of side effects, and cost.
Alternative and Adjunctive Therapies
Fibrates and Niacin
Fibrates and niacin are other classes of medications used to manage cholesterol levels. Fibrates primarily reduce triglycerides and increase high-density lipoprotein cholesterol (HDL-C), while niacin has a more potent effect on raising HDL-C. Both have been shown to reduce the risk of major coronary events, with fibrates reducing the risk by 25% and niacin by 27%. However, the use of niacin is often limited by side effects such as flushing.
Mipomersen
Mipomersen, an antisense inhibitor of apolipoprotein B synthesis, has shown promise in patients with homozygous familial hypercholesterolemia, a condition characterized by extremely high LDL-C levels. In a randomized, double-blind, placebo-controlled trial, mipomersen significantly reduced LDL-C levels by 24.7% compared to placebo. However, it is associated with injection-site reactions and elevated liver enzymes.
Inclisiran
Inclisiran, a small interfering RNA targeting PCSK9, has demonstrated sustained reductions in LDL-C levels in patients at high cardiovascular risk. In a phase 2 trial, inclisiran reduced LDL-C levels by up to 52.6% with two doses, and the effects were maintained for up to 240 days. Inclisiran was generally well-tolerated, with injection-site reactions being the most common adverse event.
ETC-1002 (Bempedoic Acid)
ETC-1002, also known as bempedoic acid, is an oral medication that has shown efficacy in lowering LDL-C levels, both alone and in combination with ezetimibe. In a phase 2b trial, ETC-1002 reduced LDL-C by up to 30% as monotherapy and by up to 48% when combined with ezetimibe. It was well-tolerated, with similar rates of muscle-related adverse events in both statin-intolerant and statin-tolerant patients.
CETP Inhibitors
Cholesteryl ester transfer protein (CETP) inhibitors, such as torcetrapib, have been investigated for their ability to raise HDL-C levels. While CETP inhibitors significantly increase HDL-C, their impact on cardiovascular outcomes has been disappointing. A meta-analysis found no significant effect on all-cause mortality, coronary heart disease mortality, myocardial infarction, or stroke. This suggests that simply raising HDL-C levels may not translate into reduced cardiovascular events, especially in the era of widespread statin use.
Conclusion
While statins remain the cornerstone of cholesterol-lowering therapy due to their proven efficacy and safety, alternative and adjunctive therapies such as fibrates, niacin, mipomersen, inclisiran, and ETC-1002 offer additional options for patients with specific needs or intolerances. However, the clinical benefits of raising HDL-C pharmacologically remain uncertain, highlighting the complexity of lipid management in cardiovascular disease prevention.
Sources and full results
Most relevant research papers on this topic